An overview of neuroendocrine tumors and comprehensive insight on the novel targeted therapies that are improving outcomes for patients.
EP. 1: Understanding the Diagnosis and Prognosis of Neuroendocrine Tumors
Diane Reidy-Lagunes, MD, provides an overview of neuroendocrine tumors, along with specific considerations for optimal diagnosis and prognostication.
EP. 2: Neuroendocrine Tumor Pathogenesis and Molecular Testing
Expert insight on the pathogenesis of neuroendocrine tumors and the best use of molecular testing to inform treatment decisions.
EP. 3: An Overview of Treatment Approaches for Neuroendocrine Tumors
Standard treatment pathways for patients with neuroendocrine tumors involving systemic therapy, surgery, and radiation.
EP. 4: Neuroendocrine Tumors: Factors That Inform Therapy Selection
A detailed explanation on how disease and patient factors inform selection from the treatment armamentarium for neuroendocrine tumors.
EP. 5: Systemic Therapy for Advanced Neuroendocrine Tumors
Diane Reidy-Lagunes, MD, outlines goals of therapy and selection of systemic therapy for patients with neuroendocrine tumors.
EP. 6: Advanced Neuroendocrine Tumors: VEGF-Targeted Therapies
Expert reflections on VEGF-targeted therapy’s role in the treatment of patients with neuroendocrine tumors.
EP. 7: Advanced Neuroendocrine Tumors: Clinical Trials With Surufatinib
Considerations for use of surufatinib in patients with neuroendocrine tumors in light of the SANET-p and SANET-ep clinical trials.
EP. 8: Future Directions in the Management of Neuroendocrine Tumors
Looking toward the future management of neuroendocrine tumors, Diane Reidy-Lagunes, MD, shares insight on possible therapy evolutions and ongoing unmet needs.
EP. 9: The Nature of Neuroendocrine Tumors
Expert insight on the subtypes of neuroendocrine tumors and current understanding of the disease microenvironment.
EP. 10: Neuroendocrine Tumors: Options for Initial Therapy
Matthew H. Kulke, MD, provides a broad overview of initial therapy options available for patients with neuroendocrine tumors.
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC